During the last decade, the importance of the complement system has become evident in both clinical medicine and complement therapeutics. This increased interest means a more prominent need for assays to evaluate complement activity.
Activity biomarkers are used to determine whether deficiencies, overactivation or dysregulation in the complement system are causing, or contributing to, a person's disease or condition.
In order to exactly measure such activation, assays for quantification of products formed during activation are required.
The Svar Complement activity biomarkers give valuable intelligence in several situations where one might suspect that complement activation plays a role in the disorder. The Svar assays for complement activity biomarkers are developed to target the unique neoepitopes only presented at the complement component or complex when activated.
The Svar Complement C4d, launched in 2018, and the Complement TCC are flexible and easy to use enzyme immunoassays with ready to use reagents and short incubation times leading to reduced hands-on-time for the user.
The Svar complement activity biomarkers are well suited for studies of complement activation in drug development and medical devices, i.e. biological safety testing and as part of the recommended tests for assessing complement activation according to ISO standard 10993-4 for hemocompatibility testing.